Santa Barbara, CA, September 16, 2014 – Researchers found that ActiveLife Scientific’s Bone Material Strength index (BMSi) test identifies patients with bone fragility fracture when today’s standard bone health tests cannot. Over 160 million people worldwide are at risk of fracture for reasons that cannot be detected by today’s standard bone strength test, the DEXA bone density scan. Study results presented at the 2014 American Society for Bone and Mineral Research Annual Conference (ASBMR) in Houston demonstrated how BMSi could be capable of identifying those at risk.
According to the ASBMR presentation by Dr. Natasha Appelman-Dijkstra of the Leiden University Medical Center in The Netherlands, “This study is the first to show that Bone Material Strength [index] is significantly lower in fracture patients with osteopenia and comparable to fracture patients with osteoporosis. Our data suggest an aspect of altered bone quality contributing to bone fragility independent of BMD.”
“The new BMSi test is being validated by bone health experts at top medical research institutions including Mayo Clinic, Harvard, Columbia University and their international equivalents,” stated Dr. Brian Kopeikin, North American Medical Director of ActiveLife Scientific, the maker of the BMSi test. “We congratulate the study investigators on their extremely important early findings that BMSi is associated with patients who are fracturing and currently have no test to accurately diagnose their risk.”
“The BMSi test is currently part of research studies worldwide, with over 1,000 people tested to date. The next step is to expand the clinical studies and eventually file for FDA approval of the test in the US,” stated Davis Brimer, Chief Executive Officer of ActiveLife Scientific. “We are collaborating with the best scientists and doctors from around the world to validate BMSi, however in order to deliver the test to the doctors’ office we will need more money to pursue formal clinical trials.”
About ActiveLife Scientific
ActiveLife is a Santa Barbara, California startup company that invents and delivers technology to empower active living. To be precise, they make instruments that test the quality of bones and tissues so scientists can discover better treatments, medical professionals can deliver better results, and people can live actively throughout their entire life. The company’s flagship products are used worldwide by innovative and thought leading medical researchers. BioDentTM Reference Point Indenter (RPI) is a bench-top instrument used by life scientists to measure bone and tissue material properties. OsteoProbe® RPI is a hand-held instrument designed for bone researchers to use in translational and clinical research.
A groundbreaking discovery in 2005 led renowned UC Santa Barbara professor and inventor Dr. Paul Hansma – an inventor for Atomic Force Microscopy - to the invention and development of Reference Point Indentation (RPI). RPI introduces unrivaled possibilities for direct, accessible and affordable measures of the quality of the body’s bones and tissues. ActiveLife was founded in 2007 to empower people to live actively. Learn more at www.activelifescientific.com.
BioDentTM and OsteoProbe® are currently For Research Use Only. Not for use in diagnostic procedures.
About Osteopenia and Bone Fracture Risk
According to the International Osteoporosis Foundation, half of the over 9 million bone fragility fractures that occur every year are associated with people who have very low calcium bone mineral density (BMD), called Osteoporosis. The 4.5 million other fractures occur in people with moderately low calcium BMD, called Osteopenia. The physicians’ conundrum is that the DEXA cannot identify people who may fracture in the over 160 million people who fall in the Osteopenia category. It is in this Osteopenia category that ActiveLife’s OsteoProbe Bone Material Strength index (BMSi) test may one day play a role.
About The American Society for Bone and Mineral Research
The 2014 Annual Meeting of the American Society for Bone and Mineral Research, held in Houston, Texas, is the world’s leading international bone research conference. Its worldwide membership of 4,000 includes research scientists, clinical investigators, physicians, and other healthcare practitioners with diverse interests in the bone health and related fields.